Biotech News

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

Tango Therapeutics (TNGX)Tango Therapeutics2026-06-25 13:46 ESTEarnings

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call.

Open original release

Related news

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Sung Lee to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

View all latest news

Tango Therapeutics

Tango Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TNGXTango Therapeutics2026-06-26 06:20 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-26 06:20 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-26 06:20 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-26 06:20 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-06-26 06:20 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States